National Institute for Health and Clinical Excellence (NICE)
Motor neurone disease guidelines to have "hugely significant" impact on care
Updated motor neurone disease guidelines will have a “hugely significant” impact on care, according one national charity.
The guidelines, published by NICE, aim to improve and standardise care for people who have motor neurone disease (MND).
MND is a group of rare, incurable, progressive, fatal neurodegenerative diseases that attack the motor neurones in the brain and spinal cord. Around 1100 people will develop MND each year in the UK and around 5000 adults currently live with the disease.
Typical symptoms include muscle weakness, wasting, cramps, problems with speech and swallowing, and rare cases, breathing problems. Most people with MND die within 2-3 years of developing symptoms, but 25% are alive at 5 years, and between 5 and 10% are alive at 10 years.
Since there is no cure for MND, the aim of care for the diseases is to maintain ability to function and enable those with MND and their family members to live as full a life as possible.
Currently, care for MND varies. While MND care centres and networks provide coordinated multidisciplinary care, some people with MND are left isolated and their care is less than ideal.
The NICE guidelines include recommendations that cover the care of people with MND from diagnosis until preparation for end of life care to help improve and standardise assessment and management of the disease.
Provide information and support at diagnosis
Among the new recommendations are that information about the diagnosis, prognosis and management of MND should be given by a consultant neurologist.
The consultant should have up-to-date knowledge and experience of treating people with MND unless it is clinically necessary to give the diagnosis in an urgent situation.
People with MND should be provided with information and support at diagnosis or when they ask for it. Information should be oral and may include what MND is, its types and possible causes, and how the disease might progress.
When MND is suspected of confirmed, the person’s GP should be informed without delay and information should be provided about the likely diagnosis.
Ensure a specialist multidisciplinary approach
The updated guidelines also call for coordinated care for people with MND, using a clinic-based specialist MND multidisciplinary approach.
The clinic may be community or hospital based, and include healthcare professionals and social care practitioners with expertise in MND, and staff who see people in their home.
NICE says that multidisciplinary care improves survival in patients with MND, with evidence drawn from models of multidisciplinary care that use a clinic based approach.
Further recommendations call for the multidisciplinary team to be tailored to a person’s needs, and that triggers should be in place if there is a significant change in symptoms identified by the person, family members and/or carers (as appropriate), or healthcare professionals.
Elsewhere, the guideline includes recommendations on psychological and social care support, planning for palliative care, managing symptoms, and care for speech and communication needs.
‘Hugely significant MND guideline will help shape future care’
Sally Light, Chief Executive of the Motor Neurone Disease Association, said: "The MND Association strongly welcomes the publication of the NICE guideline on MND. This long awaited guideline has come about after more than four years of campaigning by the Association and our supporters.
“It is a hugely significant document that sets out in detail what good care looks like and how it should be delivered. It will shape future care and have a huge influence over the quality of life for people living with MND and their families and carers. We look forward to working with our members and supporters to ensure the NICE guideline on MND has a positive impact on the care and support available to people with MND, their families and carers in England, Wales and Northern Ireland."
Commenting on the guidance, Dr David Oliver, Consultant in Palliative Care and Chair of the group which developed the guideline, said: “The guideline will enable all people with MND across the country, whether in hospital, at home, in a care home or hospice, to receive care that is co-ordinated, consistent, comprehensive and responsive to their needs, that will improve their quality of life and support them, and their families. The challenge is now to see the recommendations put into practice in services across the country.”
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE recommends offering app-based treatment for people with insomnia instead of sleeping pills20/05/2022 12:10:00
Hundreds of thousands of people suffering from insomnia who would usually be prescribed sleeping pills could be offered an app-based treatment programme instead, NICE has said
Draft NICE guidance recommends innovative technology used to establish whether breast cancer has spread17/05/2022 12:15:00
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread, after the technology was recommended in draft NICE guidance
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS17/05/2022 11:15:00
Durvalumab recommended as an option for treating non-small-cell lung cancer (NSCLC).
Women with moderate to severe fibroids set to be offered new one-a-day treatment following final draft guidance from NICE16/05/2022 14:15:00
Around 4,500 women with uterine fibroids will be eligible for a new oral treatment after NICE recommended relugolix with estradiol and norethisterone acetate (also called Ryeqo and made by Gedeon Ritcher UK) in final draft guidance.
NICE outlines steps needed to put ME/CFS guideline into practice12/05/2022 16:10:00
NICE has today, International ME Awareness Day (Thursday, 12 May 2022) published its implementation statement which sets out the practical steps needed to put its recent guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) into
Healthier lifestyle can help to ease osteoarthritis symptoms says NICE03/05/2022 16:15:00
Exercise has an important role to play in helping people living with osteoarthritis NICE says in draft updated guidelines published recently (29th April 2022) on the care and management of people with the condition.
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation14/04/2022 16:10:00
New potentially life-extending lung cancer drug which targets a specific genetic mutation recommended by NICE.
NICE reaches important milestone in the UK’s efforts to tackle antimicrobial resistance.13/04/2022 11:15:00
Two new antimicrobial drugs – cefiderocol and ceftazidime–avibactam – are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model after NICE yesterday (Tuesday, 12 April 2022) published draft guidance estimating their value to the NHS.